T2DM patients with HF may benefit from SGLT2 inhibitor therapy

Slides:

Advertisements

Similar presentations

Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.

Advertisements

analysis from the SHIFT study

Hazard of incident coronary heart disease by diabetes status, with or without elevation of troponin T No diabetes Pre- diabetes Diabetes No diabetes Pre-

Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.

Clinical Outcomes with Newer Antihyperglycemic Agents

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Main results Swedberg K, et al. Lancet. 2010;376(9744):

Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.

Sglt-2 insulin Matthews D, Fulcher G, Perkovic V, et al. Ef  cacy and safety of canagliflozin,an inhibitor of sodium glucose co-transporter 2, added.

Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.

Relationship of background ACEI dose to benefits of candesartan in the CHARM-Added trial.

New 2011 SHIFT quality of life substudy Quality of life ( QoL) in heart failure: where do we stand? Therapies that have survival benefits either have a.

Canagliflozin Cardiovascular Safety. 2 Potential CV protection pathways of SGLT2i Diab Vasc Dis Res Mar;12(2):

Date of download: 6/26/2016 Copyright © The American College of Cardiology. All rights reserved. From: Clinical Effectiveness of CRT and ICD Therapy in.

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:

Heart Failure Events and All-cause Death in New Users of SGLT-2 inhibitors vs other glucose-lowering drugs - consistent risk reduction across patient groups.

Clinical Outcomes with Newer Antihyperglycemic Agents

Clinical Outcomes with Newer Antihyperglycemic Agents

Mikhail Kosiborod, MD Professor of Medicine (Cardiology)

Taieb V, et al. Value Health Nov;18(7):A598.

Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals

LEADER trial: Primary Outcome

Neal B, et al. Diabetes Care 2015;38:403–411

SGLT2 INHIBITORS REDUCE RISK OF HEART FAILURE IN TYPE 2 DIABETICS: A META-ANALYSIS Tariq Jamal Siddiqi1; Muhammad Shariq Usman1; Fahad Khan1; Nawaz Lashari1;

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

Risk of Heart Failure Among Postmenopausal WomenCLINICAL PERSPECTIVE

SGLT2 Inhibitors: What Do the Data Mean for My Patients?

Diabetes mellitus SGLT2 inhibitors: Novel concepts (cont’d):

Choosing glucose-lowering medication in those with established ASCVD, HF, and CKD. CV, cardiovascular; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1.

Baseline characteristics of patients

Impacting CV Risk With Diabetes Medications

Impacting CV Risk With Diabetes Medications

Diabetes and CV Risk Reduction: Cardiologists’ Perspectives on the Latest Outcomes Data.

Type 2 Diabetes Management: Where Are We Heading in Our Efforts to Control CV Risk?

Dileep Raman et al. JACEP 2017;3:

T2DM, CV Risk, and SGLT2 Inhibition in the Spotlight

The Role of the Kidney in Glucose Control

Jonathan M. Behar et al. JACEP 2017;3:

Baseline Characteristics

Mintu P. Turakhia et al. JACEP 2016;2:

Tackling CV Risk in Type 2 Diabetes -- Gaps Between Guidelines and Clinical Practice?

Svend A. Mortensen et al. JCHF 2014;2:

Connie W. Tsao et al. JCHF 2016;4:

Baseline characteristics for patients with diabetes in ASCOT-LLA Part I P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157.

Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.

Maneesh Sud et al. JCHF 2017;5:

Baseline Characteristics by hs-CRP

Forest plot showing the association between center-level characteristics and death-censored technique failure after adjusting for age, sex, race, body.

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

CANVAS programe subanalyses HR (95%CI): 0.65 ( ) ( ) ( ) ( )

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

Glucose-lowering medication in type 2 diabetes: overall approach.

Connie W. Tsao et al. JCHF 2016;4:

Associations between type of MI and incident HF

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Baseline Clinical Characteristics of All Patients and Patients Grouped by Statin Therapy - Part I H. Fukuta et al. Circulation 2005;112:

Number of patients who would have benefitted from addition of ACE inhibitor (ACEi), beta blockers (BB) or optimal therapy (one or both of ACEi and BB)

Lifetime heart failure risk*

The benefit of evolocumab treatment is consistent regardless of inflammation level HR %CI ARR 1.6% 1.8%

Jeffrey Senfield et al. JACEP 2017;3:

Increase of physical activity over time associated with lower HF risk

A: Forest plot of the HR of AE of bone fracture between the saxagliptin and placebo groups across subgroups by demographic and medical history parameters.

Risk of venous thromboembolism by ABO blood type, factor V Leiden R506Q and prothrombin G20210A mutations among individuals in the Copenhagen General.

LDL-c reductions below 1

Glucose-lowering medication in type 2 diabetes: overall approach.

HR for mortality in ischemic heart disease.

HR for myocardial infarction.

Identification of thresholds for significant renal recovery in relation to patient and renal survival. Identification of thresholds for significant renal.

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Presentation transcript:

T2DM patients with HF may benefit from SGLT2 inhibitor therapy A CANVAS program analysis All patients Patients with a history of HF at baseline Patients without a history of HF at baseline Canagliflozin better Placebo better SGLT2: sodium glucose cotransporter 2; CANVAS: Canagliflozin Cardiovascular Assessment Study; HR: hazard ratio; LCL: lower confidence limit; UCL: upper confidence limit; CI: confidence interval; HF: heart failure; CV: cardiovascular; T2DM: type 2 diabetes mellitus Radholm et al. Circulation 2018